MapLight Therapeutics 的股价在盘前交易中遭遇重挫,跌幅高达55.7%。这一剧烈波动源于公司公布了其针对精神分裂症药物的中期试验结果。市场对此次披露的数据反应极为负面,投资者信心受挫,导致股价在开盘前便大幅跳水。该公司正面临严峻考验,后续发展引人关注。
MapLight Therapeutics 的股价在盘前交易中遭遇重挫,跌幅高达55.7%。这一剧烈波动源于公司公布了其针对精神分裂症药物的中期试验结果。市场对此次披露的数据反应极为负面,投资者信心受挫,导致股价在开盘前便大幅跳水。该公司正面临严峻考验,后续发展引人关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.